Fat Loss (Lipoatrophy)


Theratechnologies Announces Promising 52-week Study Data on Tesamorelin (TH9507) for Treatment of Lipodystrophy in HIV Patients - 10/05/07

No Significant Body Composition Differences between Patients Treated with Atazanavir vs Atazanavir/ritonavir  - 3/20/07

Compared to Efavirenz, Lopinavir/Ritonavir Has Less Lipoatrophy When Given with NRTI  - 3/09/07

Significant Sparing of Lipoatrophy Results from Treatment of HIV Patients with Kaletra + Combivir Induction followed by Kaletra Monotherapy Compared with Sustiva + Combivir - 3/02/07

Body Shape Changes in Women who Discontinue d4T  1/16/07

Rosiglitazone and Metformin Improve Insulin Sensitivity, but Minimal Effect on Body Fat  12/12/06

Does Discontinuation of Stavudine or Protease Inhibitor Therapy Improve HIV-related fat Redistribution in Men? - 5/05/06

Outcomes from Discontinuing Stavudine or Protease Inhibitor Therapy for HIV Fat Redistribution- 2/24/06

Metabolic and Adverse Events Report from the 13th CROI - 2/21/06

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Treatment-naive HIV Patients - 1/17//06

Lipid Changes in a Randomised, 48-week, Open Label Comparative Study of Tenofovir DF vs. Abacavir as Substitutes for a Thymidine Analog in Persons with Lipoatrophy: The RAVE Study. G Moyle and others. - 12/18/05

Increase in Limb Fat after Stopping Nucleoside Analogue Therapy Is Not Associated with Decreased Visceral Fat and Has Different Risk Factors - 12/09/05

Risk Factors for Lipoatrophy - 12/09/05

Supplementation with Creatine Does Not Improve the Benefits from Resistance Exercise Training in HIV Patients - 12/09/05

Single Dose of Amprenavir Does Not Induce Insulin Resistance - 12/09/05

Body Fat Changes in Children with HIV Infection - 12/09/05

Visceral Fat Mass and the Risk of Insulin Resistance and Cardiovascular Disease - 12/09/05

HIV Patients with Lipoatrophy Have High Levels of Anxiety and Depression and Low Self Esteem with Poorer Quality of Life - 12/09/05

Anthropometry and Bioimpedance Are Inexpensive Office-based Assessments of Body Shape Changes in Patients on HAART - 12/09/05

Is Fat Mass Ratio an Objective Tool for Diagnosis of HIV Lipodystrophy Syndrome Diagnosis? - 12/09/05

Patient Perspective Is Essential in Medical Decision-making about Lipodystrophy - 12/09/05

Body Shape Changes 1 and 2 Years after Switch to Tenofovir from Stavudine - 12/09/05

CD4+ Cell Count, Viral Load and HAART Independently Predict Body Composition Changes in HIV Positive Adults - 11/30/05

FRAM Study Finds No Association between Fat Loss and Fat Accumulation in Men with HIV on Antiretroviral Therapy - 10/03/05

Comparison of Rosiglitazone and Metformin for Treatment of HIV-related Lipodystrophy - 9/19/05

Impact of Rosiglitazone Treatment on the Bioavailability of Antiretroviral Drugs in HIV Patients - 9/19/05

Fat Loss and Fat Accumulation in HIV Patients Are Distinct Syndromes with No Common Factor Underlying Their Prevalence - 6/24/05

Therapeutic Approaches to Combating Lipoatrophy: Do They Work? - 6/17/05

Metabolic Benefits But No Morphological Improvements 24 Months after Replacing a Protease Inhibitor with Abacavir, Efavirenz or Nevirapine - 6/01/05

Fat Redistribution Predicts Cardiac Risk in Women with HIV - 5/27/05

Body Fat Changes in Treatment-naive Patients on PI- and NNRTI-based HAART in the Swiss HIV Cohort Study: Fat Loss More Likely with Increasing Stavudine Use - 5/23/05

Body Image in Patients with HIV: Assessment of a New Psychometric Measure - 4/06/05

Treatment of Facial Lipoatrophy with Injections of Polylactic Acid (Sculptra) - 3/21/05

Increased Adipocyte Apoptosis in Lipoatrophy Improves Within 48 Weeks of Switching Patient Therapy from Stavudine to Abacavir or Zidovudine - 3/18/05

Data at 12th CROI Builds Optimism on Metabolic and Morphologic Management - 3/11/05

Antiretroviral Therapy-related Adverse Events Data Presented at the 12th CROI - 3/11/05

Poly-L-lactic Acid Helps in HAART-related Facial Wasting - 3/02/05

Body Shape Changes in a Cohort of HIV Positive and HIV Negative Injection Drug Users - 2/02/05

Lipoatrophy and Mitochondrial DNA Assays - 1/21/05

Improvements in Lipoatrophy, Mitochondrial DNA Levels and Fat Apoptosis after Replacing Stavudine with Abacavir or Zidovudine - 1/10/05

Fat Distribution in HIV-infected Women in the United States - 1/07/05

Studies of Polylactic Acid Continue to Show Promise in Treatment of HIV-related Facial Lipoatrophy - 12/13/04

Custom-built Implants Useful for Facial Wasting of HAART-related Lipodystrophy - 11/17/04

6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - 11/17/04

Highly Purified Silicone Oil (Silskin) for Treatment of HIV-related Facial Lipoatrophy: A Pilot Study - 10/15/04

Fat Distribution Is Altered in HIV-infected Men Without Clinical Evidence of the HIV Lipodystrophy Syndrome  - 09/20/04

Acute Hepatic Cytolysis Associated with Atazanavir: A Case Report  - 09/08/04

First Case Report of Development of Multiple Lipomas During Treatment with Rosiglitazone for HIV-related Lipoatrophy  - 08/23/04

Prevalence of Lipoatrophy and Mitochondrial DNA Content in HIV Patients Randomly Allocated to Zidovudine- or Stavudine-based Therapy  - 08/16/04

FDA Approves Sculptra as First Therapy for HIV-related Facial Lipoatrophy - 08/04/04

Lipids, Metabolic Syndrome and Risk Factors for Future Cardiovascular Disease: Highlights from the 15th International AIDS Conference - 07/28/04

Changes in Lipoatrophy with Change to Intermittent Therapy - 07/28/04

Lipoatrophy with Atazanavir or Efavirenz - 07/28/04

After Long-term HAART, Patients Have Pronounced Lipoatrophy Without Truncal Fat Accumulation Compared with Background Population - 07/21/04

Polymethylmethacrylate (PMMA) for Facial Atrophy Treatment: 5 Years Follow-up - 07/12/04

Use of a Severity Index Helps to Characterize and Quantify HAART-related Facial Lipoatrophy  - 07/12/04

Body Composition Changes in 308 Norwegian HIV-positive Patients - 06/25/04

Impact of Switching Antiretroviral Therapy on Lipodystrophy and Other Metabolic Complications: A Review - 06/23/04

High Plasma Level of Interleukin-18 Appears in HIV Patients with Lipodystrophy - 06/09/04

Metabolic Effects of Rosiglitazone in HIV Lipodystrophy 05/26/04

Reversibility of Lipoatrophy in HIV Patients 2 Years After Switching from a Thymidine Analogue to Abacavir - 4/23/04

Regression of Lipodystrophy in HIV Patients on Therapy with New Protease Inhibitor Atazanavir 04/14/04